Why Tesamorelin Targets Visceral Fat Specifically

Tesamorelin doesn't move all fat the same way. In the published Phase 3 trial, visceral fat (the depot around the organs) dropped 15 to 18 percent at 26 weeks of 2 mg daily dosing. Subcutaneous fat (the depot under the skin) barely moved by comparison.

That asymmetry is not a quirk of the trial design. It's a feature of GH axis biology. This piece walks through why visceral fat responds to growth hormone faster than subcutaneous fat, how tesamorelin pushes the GH pulse without shutting down feedback, and the standard research cycle that mirrors the trial protocol.

The depot difference: why visceral fat moves first

Visceral fat and subcutaneous fat look similar on a body scan, but they behave like two different tissues at the cellular level. Visceral fat sits around the organs in the abdominal cavity. Subcutaneous fat sits under the skin. The two depots differ in three ways that matter for tesamorelin biology:

• GH receptor density. Visceral fat has more growth hormone receptors per cell than subcutaneous fat. More receptors means a stronger response to the same GH pulse.
• Lipolytic responsiveness. Visceral fat releases fatty acids into the bloodstream faster than subcutaneous fat when GH is high. The cell machinery that breaks down stored triglycerides is more active there.
• Turnover rate. Visceral fat cycles its lipid stores faster. That faster turnover is what lets the depot shrink visibly over weeks while subcutaneous fat needs months.

Push pulsatile GH release, and the depot that responds fastest is the one that shrinks first. That depot is the visceral one. The trial data matches this exactly.

What tesamorelin is

Tesamorelin is a synthetic 44-amino-acid analog of growth hormone releasing hormone (GHRH). The synthesis adds a small modification at one end (a trans-3-hexenoic acid cap) that protects the peptide from the enzymes that would normally chew it up in the bloodstream. That cap extends the plasma half-life, which is what makes daily subcutaneous dosing work.

Once injected, tesamorelin binds the GHRH receptor on the pituitary gland and triggers a pulse of growth hormone release. The pulse is the key word. Native GH is released in bursts throughout the day, with the largest burst during deep sleep. Tesamorelin respects that pulse pattern, which is why the body's feedback loops keep functioning. Continuous, non-pulsatile GH (the kind given as recombinant growth hormone) shuts those loops down. GHRH analogs do not.

What does the Tesamorelin Phase 3 trial show in detail?

The pivotal trials enrolled adults with HIV-associated visceral adipose research targets. The reported outcomes:

• Mean visceral adipose tissue reduction of 15 to 18 percent at 26 weeks of 2 mg daily subcutaneous dosing.
• Mean IGF-1 rise of roughly 60 to 80 percent over baseline at 26 weeks.
• Improvements in lipid panel, especially triglycerides.
• Side effect profile in line with the GHRH class: injection site response, occasional fluid retention, mild paresthesia (tingling), modest impact on glucose metabolism that warranted monitoring.

Phase 3 evidence in non-HIV adult research populations is more limited. The trial program focused tightly on the visceral adipose endpoint in the registered indication.

What is the standard Tesamorelin research cycle structure?

Many researchers run 1 mg daily for the 12 to 26 week window as a cost-balanced midpoint relative to the 2 mg Phase 3 protocol. The full 2 mg dose produces the largest reported signal in the published data. Morning injection on an empty stomach is the most common timing in the research community, since that timing best preserves the natural overnight GH pulse.

What are the Tesamorelin side effects from the literature?

• Injection site response. Mild redness, tenderness, or itching at the subQ site. Common in the first 1 to 2 weeks. Usually gone within hours of each shot.
• Mild paresthesia. Tingling or numbness in the hands or feet. Often resolves with a dose drop or a short wash-out.
• Fluid retention. Reported in the extremities. Resolves on dose adjustment.
• Glucose metabolism shift. Modest signal in the Phase 3 data. Baseline fasting glucose and HbA1c monitoring at week 12 and week 24 is recommended.
• Headache. Common in the first 1 to 2 weeks. Self-limiting.

How do you reconstitute and store Tesamorelin?

Aion ships tesamorelin in 5 mg and 10 mg vials. Standard mix for the 5 mg vial: 2.5 mL of bac water, giving 2 mg per mL or 20 mcg per insulin syringe unit. A 1 mg dose at that concentration is 0.5 mL or 50 units. A 2 mg dose is 1.0 mL or 100 units (a 1 mL syringe is easier than the small insulin barrel at that volume). Full walk-through in our reconstitution guide.

• Lyophilized, sealed: refrigerated at 2 to 8 C, stable for months
• Lyophilized, long-term: minus 20 C freezer for multi-year storage
• Reconstituted with bac water: refrigerated at 2 to 8 C, 4 week use window

What researchers track on a tesamorelin cycle

1. Bodyweight, weekly morning average
2. Waist circumference, monthly
3. Body composition (DEXA or equivalent), baseline and at week 12 and week 26
4. IGF-1 blood marker, baseline and at week 8 and week 26
5. Fasting glucose, HbA1c, lipid panel, baseline and at week 12 and week 26
6. Sleep quality and recovery score, daily via wearable

What is the Tesamorelin bottom line?

Tesamorelin is the GH axis research compound with the strongest published Phase 3 evidence. The visceral fat signal is real, the mechanism is well understood, and the depot asymmetry (visceral first, subcutaneous a long way behind) is the most useful piece of biology for protocol design. Pick the dose that matches the budget, run the full 12 to 26 week window, log the waist measurement monthly, and let the cycle compound.

For the stack-friendly alternative in the same GH axis category, see /research/cjc-1295-ipamorelin.